Parents’ perceptions of the KiVa anti-bullying program
4
Citation
43
Reference
10
Related Paper
Citation Trend
Abstract:
The KiVa anti-bullying program is an evidence based whole-school intervention and prevention program that has been implemented in a small number of New Zealand schools to help address high rates of bullying behaviors. Parents are a key component of the whole-school program as without parental support the ongoing sustainability of the program within individual schools could be compromised. Parents of children in schools that had implemented the program for at least one year were invited to complete an online anonymous survey about their knowledge, perceptions and experiences of KiVa. The initial screening question was answered by 409 participants and showed that over a quarter of participants had no knowledge of KiVa prior to being invited to complete the study. The experiences of the 223 participants who completed the main section of the survey (including demographic information) varied considerably in terms of the information received and their overall perceptions of the program. There were 57 parents who provided information about their direct experiences with the KiVa program, half of whom had a positive experience of KiVa and were likely to recommend it. Most of the issues for those who had negative experiences were around the lack of information and poor communication from the school. Unsurprisingly, those who had a negative experience were less likely to indicate that they would recommend the program to others. The findings from this preliminary investigation highlight the importance of effective home-school communication to ensure the sustainability of the KiVa program.Keywords:
Quarter (Canadian coin)
During the first quarter of 2016, Cortellis Competitive Intelligence had 1,011 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This was a slight decrease on the last quarter (Q4 2015: 1,075) but a significant increase on the same quarter for the previous year (Q1 2015: 826). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity.
Quarter (Canadian coin)
Milestone
Cite
Citations (0)
The persistent weakness of UK economic growth figures has dominated recent economic commentary. This debate continued with the release of the Office for National Statistics‘ (ONS) preliminary estimate of GDP growth for the second quarter of this year. The ONS estimates that the economy enjoyed only a modest expansion in the second quarter: 0.2 per cent per quarter. This implies the level of output is little changed from the third quarter of 2010. ‘One-off effects’ are partly responsible for the weak growth in the second quarter. We expect GDP growth to accelerate in the third quarter of this year (see figure 1), but this increase is likely to be flattered by the events of the second quarter.
Quarter (Canadian coin)
Cite
Citations (1)
During the first quarter of 2017, Cortellis Competitive Intelligence had 1,073 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This meant a slight increase on the last quarter (1,022) and a similar volume on the same quarter for the previous 1 year (1,141). However, this quarter showed a significant augment in deals worth more than USD 0.5 billion on the last quarter (17 vs. 12). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity.
Quarter (Canadian coin)
Milestone
Cite
Citations (0)
The Austrian economy expanded at a seasonally and working day adjusted rate of 0.8 percent quarter-on-quarter in the first quarter of 2008, following +0.6 percent in the fourth quarter of 2007. On a year-on-year basis, growth accelerated to 3.5 percent in real terms. Economic activity is picking up once more on the back of strong value added growth in industry and construction. Trade and tourism also posted good results. Given the deterioration of the international environment, the outlook for activity in the coming months remains subdued. In the USA the economy grew hardly at all in the first quarter, and in Europe, too, the outlook is darkening further.
Quarter (Canadian coin)
Cite
Citations (0)
During the second quarter of 2017, Cortellis Competitive Intelligence added 967 new licensing deals (excluding mergers and acquisition deals) as part of its ongoing coverage of pharmaceutical licensing activity. This meant an 8% decrease on the previous quarter (1,050) and a 3% decrease from the same quarter in 2016 (993). This quarter also showed a significant decline in the number of deals worth more than USD 0.5 billion from the last quarter (7 vs. 17). This article will highlight a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers in the life sciences. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity.
Quarter (Canadian coin)
Milestone
Cite
Citations (0)
Quarter (Canadian coin)
Cite
Citations (0)
During the third quarter of 2016, Cortellis Competitive Intelligence had 865 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This figure shows similar deal activity compared with the same quarter of 2015 (934), and 21% less than the previous quarter, although they had similar disclosed financial sizes in comparison with the first half of 2016. This article will focus on a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestones, options and terminated deals of significance will also be presented, along with an early outlook on the last quarter of 2016's pharmaceutical licensing activity.
Quarter (Canadian coin)
Cite
Citations (0)
The 130 Quarter in Irkutsk was rebuilt more than seven years ago. Since then it has been constantly debated. The article demonstrates the results of the analysis of the Quarter’s environment with the help of two original methods. Comments made by guests of the Quarter were examined by using the frequency content analysis method. The Quarter’s environment was studied by using the key visual shot method. The author reveals the reasons why the Quarter’s environment attracts Irkutsk citizens and guests of the city. The directions of the Quarter’s development as an environmental and economically self-sufficient entity are also presented in the article.
Quarter (Canadian coin)
Cite
Citations (0)